X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (633) 633
Publication (53) 53
Conference Proceeding (30) 30
Patent (15) 15
Book Review (13) 13
Web Resource (2) 2
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (372) 372
humans (366) 366
male (222) 222
female (214) 214
middle aged (206) 206
hematology (203) 203
adult (192) 192
oncology (142) 142
aged (136) 136
transplantation (100) 100
adolescent (95) 95
cancer (73) 73
treatment outcome (70) 70
immunology (63) 63
leukemia (63) 63
young adult (62) 62
stem cells (58) 58
transplantation, homologous (57) 57
chemotherapy (55) 55
prognosis (53) 53
abridged index medicus (51) 51
hematology, oncology and palliative medicine (50) 50
aged, 80 and over (45) 45
acute myeloid-leukemia (44) 44
hematopoietic stem cells (44) 44
survival analysis (44) 44
acute myeloid leukemia (43) 43
hematopoietic stem cell transplantation (43) 43
therapy (42) 42
analysis (41) 41
retrospective studies (41) 41
leukemia, myeloid, acute - genetics (40) 40
leukemia, myeloid, acute - mortality (40) 40
recurrence (37) 37
aml (36) 36
disease-free survival (36) 36
leukemia, myeloid, acute - therapy (35) 35
research (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
acute myelogenous leukemia (33) 33
bone-marrow-transplantation (33) 33
mutation (33) 33
leukemia, myeloid, acute - drug therapy (32) 32
survival (32) 32
acute disease (31) 31
animals (31) 31
stem-cell transplantation (31) 31
risk factors (30) 30
bone marrow (29) 29
care and treatment (29) 29
hematopoietic stem cell transplantation - methods (27) 27
remission induction (27) 27
bone-marrow (26) 26
expression (26) 26
prospective studies (26) 26
versus-host-disease (26) 26
antineoplastic agents - therapeutic use (25) 25
child (25) 25
stem cell transplantation (25) 25
flow cytometry (23) 23
hematopoietic stem cell transplantation - adverse effects (23) 23
mortality (23) 23
myelodysplastic syndrome (23) 23
patients (23) 23
cell biology (22) 22
fms-like tyrosine kinase 3 - genetics (22) 22
germany (22) 22
risk (22) 22
t cells (22) 22
bone-marrow transplantation (21) 21
medicine (21) 21
health aspects (20) 20
immunotherapy (20) 20
mice (20) 20
mutations (20) 20
pharmacokinetics (20) 20
progenitor cells (20) 20
relapse (20) 20
tissue donors (20) 20
leukemia, myeloid, acute - pathology (19) 19
survival rate (19) 19
unrelated donors (19) 19
cohort studies (18) 18
gene expression (18) 18
transplantation conditioning - methods (18) 18
medicine, research & experimental (17) 17
transplants & implants (17) 17
colony-stimulating factor (16) 16
follow-up studies (16) 16
gastroenterology & hepatology (16) 16
medicine & public health (16) 16
surgery (16) 16
acute lymphoblastic-leukemia (15) 15
adults (15) 15
chemistry (15) 15
chronic myeloid-leukemia (15) 15
cytogenetics (15) 15
imatinib mesylate (15) 15
multivariate analysis (15) 15
myelodysplastic syndromes - therapy (15) 15
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 10/2012, Volume 30, Issue 29, pp. 3604 - 3610
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9850, pp. 1309 - 1316
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1250 - 1259
Journal Article
Deutsches Arzteblatt International, ISSN 1866-0452, 08/2014, Volume 111, Issue 33-34, pp. 2462 - 2465
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2000 - 2008
Journal Article
Blood, ISSN 0006-4971, 05/2015, Volume 125, Issue 21, pp. 3246 - 3252
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1035 - 1044
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 16, pp. 1487 - 1496
In this study of unrelated-donor transplantation for hematologic cancers, survival was similar with bone marrow and peripheral-blood stem-cell grafts. However,... 
PROGENITOR CELLS | ALLOGENEIC TRANSPLANTATION | MEDICINE, GENERAL & INTERNAL | COLONY-STIMULATING FACTOR | TERM-FOLLOW-UP | RANDOMIZED-TRIAL | MALIGNANCIES | LEUKEMIA | RECIPIENTS | VERSUS-HOST-DISEASE | CHRONIC GRAFT | Recurrence | Graft vs Host Disease - epidemiology | Peripheral Blood Stem Cell Transplantation - adverse effects | Histocompatibility Testing | Humans | Bone Marrow Diseases - mortality | Kaplan-Meier Estimate | Proportional Hazards Models | Leukemia - therapy | Peripheral Blood Stem Cell Transplantation - mortality | Male | Survival Rate | Cause of Death | Graft Rejection - epidemiology | Bone Marrow Transplantation - mortality | Bone Marrow Diseases - therapy | Intention to Treat Analysis | Bone Marrow Transplantation - adverse effects | Adult | Female | Unrelated Donors | Leukemia - mortality | Patient outcomes | Stem cells | Causes of | Bone marrow | Graft versus host reaction | Transplantation | Diagnosis | Comparative analysis | Graft-versus-host reaction | Cell survival | Transplants & implants | Risk groups | Syngeneic grafts | Mortality | Clinical trials | Bone marrow transplantation | Stem cell transplantation | Cardiovascular disease | Genetic diversity | Hematopoietic stem cells | Risk factors | Quality of life | Rejection | Grafts | Motivation | Peripheral blood | Histocompatibility antigen HLA | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 08/2013, Volume 123, Issue 8, pp. 3272 - 3291